MGI PHARMA, INC. Summarizes Data Presented at the 2007 American Society of Clinical Oncology Annual Meeting

CHICAGO--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, today provided highlights of data presentations made during the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting. Dacogen® (decitabine) for Injection was the subject of five posters including the presentation of efficacy data in older patients with acute myelogenous leukemia (AML) and activity observed in patients with refractory acute lymphocytic leukemia (ALL). Gliadel® Wafer (polifeprosan 20 with carmustine implant) was the subject of two posters with one detailing the impact of multimodal therapy that included Gliadel implantation, followed by treatment with radiation and concurrent temozolomide plus rotational chemotherapy, on survival in patients with primary glioblastoma. A poster discussion provided updated response and survival data from a randomized phase 2 clinical trial of Irofulven (MGI 114; hydroxymethylacylfulvene) in hormone refractory prostate cancer (HRPC) patients who failed docetaxel treatment. In addition to two posters, Aloxi® (palonosetron hydrochloride) Injection was the subject of a published abstract describing study results that differentiate the molecular interaction of Aloxi with the 5-HT3 receptor. These data provide new insight into the receptor binding mechanisms that may explain the enhanced protection from chemotherapy-induced nausea and vomiting (CINV) observed with Aloxi in clinical trials.

MORE ON THIS TOPIC